ClinConnect ClinConnect Logo
Search / Trial NCT04208516

Continuous Nerve Block Block vs Combination of Single Block Plus Intravenous Lidocaine for Postoperative Pain.

Launched by JEREMY KEARNS · Dec 19, 2019

Trial Information

Current as of July 09, 2025

Terminated

Keywords

Intravenous Lidocaine Erector Spinae Plane Block Quadratus Lumborum Block Thoracic Surgery Abdominal Surgery Continuous Peripheral Nerve Block

ClinConnect Summary

After obtaining a signed informed consent, participating patients will be randomized by computer generated random numbers to either the control group to receive continuous Erector Spinae Plane block (in the case of thoracic surgery) or continuous Quadratus Lumborum block (in the case of abdominal surgery), or the treatment group to receive single shot Erector Spinae Plane block (in the case of thoracic surgery) or single shot Quadratus Lumborum block (in the case of abdominal surgery) with postoperative intravenous lidocaine infusion. Subjects will be randomized in a 1:1 ratio. Randomizatio...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 18-90 years old
  • Primary unilateral VATS or major abdominal surgery
  • BMI 20-36, weight ≥ 50kg
  • Male and Female
  • All races
  • Exclusion Criteria:
  • Patient refusal
  • Inpatient status at the time of surgery
  • ASA class 4 or greater
  • Pregnancy
  • Non-English speaking or inability to participate in the study
  • Patients with coagulopathy or on therapeutic anticoagulation
  • Chronic steroid use
  • Opioid use disorder
  • Contraindication to performing any of the proposed blocks - active infection at the block site, systemic infection, allergy to local anesthetic medications
  • Patients undergoing second surgery or urgent/emergent surgery
  • Patients weighing \< 50kg
  • History of chronic pain and/or opioid tolerant
  • Anticipated requirement for patient-controlled analgesia (PCA)
  • Allergy or intolerance to any medication specified in the study protocol or postoperative pain management regimen
  • Liver disease

About Jeremy Kearns

Jeremy Kearns is a dedicated clinical trial sponsor specializing in the design, execution, and oversight of innovative research studies aimed at advancing medical knowledge and treatment options. With a strong emphasis on patient safety and ethical standards, Kearns leverages extensive experience in clinical research to collaborate with diverse stakeholders, including healthcare professionals, regulatory bodies, and research institutions. Committed to fostering scientific integrity and transparency, he ensures that each trial is conducted with rigor and precision, ultimately contributing to the development of effective therapies and improved patient outcomes.

Locations

Pittsburgh, Pennsylvania, United States

Patients applied

0 patients applied

Trial Officials

Jacques E Chelly, MD, PhD, MBA

Principal Investigator

University of Pittsburgh Medical Center

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials